Combination of MEK-ERK inhibitor and hyaluronic acid has a synergistic effect on anti-hypertrophic and pro-chondrogenic activities in osteoarthritis treatment
- 840 Downloads
We hypothesised that a potentially disease-modifying osteoarthritis (OA) drug such as hyaluronic acid (HA) given in combination with anti-inflammatory signalling agents such as mitogen-activated protein kinase kinase–extracellular signal-regulated kinase (MEK-ERK) signalling inhibitor (U0126) could result in additive or synergistic effects on preventing the degeneration of articular cartilage. Chondrocyte differentiation and hypertrophy were evaluated using human OA primary cells treated with either HA or U0126, or the combination of HA + U0126. Cartilage degeneration in menisectomy (MSX) induced rat OA model was investigated by intra-articular delivery of either HA or U0126, or the combination of HA + U0126. Histology, immunostaining, RT-qPCR, Western blotting and zymography were performed to assess the expression of cartilage matrix proteins and hypertrophic markers. Phosphorylated ERK (pERK)1/2-positive chondrocytes were significantly higher in OA samples compared with those in healthy control suggesting the pathological role of that pathway in OA. It was noted that HA + U0126 significantly reduced the levels of pERK, chondrocyte hypertrophic markers (COL10 and RUNX2) and degenerative markers (ADAMTs5 and MMP-13), however, increased the levels of chondrogenic markers (COL2) compared to untreated or the application of HA or U0126 alone. In agreement with the results in vitro, intra-articular delivery of HA + U0126 showed significant therapeutic improvement of cartilage in rat MSX OA model compared with untreated or the application of HA or U0126 alone. Our study suggests that the combination of HA and MEK-ERK inhibition has a synergistic effect on preventing cartilage degeneration.
KeywordsOsteoarthritis Mitogen-activated protein kinase Extracellular signal-regulated kinase signalling Animal model Hyaluronic acid
The authors would like to thank NHMRC, Australian Orthopaedic Association and Prince Charles Hospital Foundation for providing the funding. The authors would also like to thank the staff at the Medical Engineering research facility for assisting the animal work.
The authors declare no conflict of interest.
- 3.Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, Beary J, Aronstein WS, Spector TD (2007) Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 9:R109PubMedCrossRefGoogle Scholar
- 4.Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J (2003) In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum 48:1582–1593PubMedCrossRefGoogle Scholar
- 6.Sondergaard BC, Schultz N, Madsen SH, Bay-Jensen AC, Kassem M, Karsdal MA (2010) MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation—divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation. Osteoarthr Cartil 18:279–288PubMedCrossRefGoogle Scholar
- 13.Tang JL, Chen WP, Xiong Y, Hu PF, Wu LD (2010) The anti-inflammatory effects of apocynin, inhibitor of NADPH oxidase, contrasting hyaluronic acid on articular cartilage during the development of osteoarthritis in a rabbit model. Biomed Pharmacother. doi: 10.1016/j.biopha.2010.08.002
- 20.Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K, Moskowitz MA, Bonventre JV, Alessandrini A (2001) Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A 98:11569–11574PubMedCrossRefGoogle Scholar
- 21.Cho DG, Mulloy MR, Chang PA, Johnson MD, Aharon AS, Robison TA, Buckles TL, Byrne DW, Drinkwater DC Jr (2004) Blockade of the extracellular signal-regulated kinase pathway by U0126 attenuates neuronal damage following circulatory arrest. J Thorac Cardiovasc Surg 127:1033–1040PubMedCrossRefGoogle Scholar
- 23.Mankin HJ, Buckwalter JA (2000) Articular cartilage structure, composition and function, 2nd edn. American Academy of Orthopaedic Surgeons, RosemontGoogle Scholar
- 35.Provot S, Nachtrab G, Paruch J, Chen AP, Silva A, Kronenberg HM (2008) A-raf and B-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes. Mol Cell Biol 28:344–357PubMedCrossRefGoogle Scholar